Recombinant Streptococcus equi subsp. equi GTPase Era (era)

What is Streptococcus equi subsp. equi and why is it significant for research?

Streptococcus equi subsp. equi is the causative agent of equine strangles, a highly contagious respiratory disease in horses that causes significant morbidity and economic losses in the equine industry. This pathogen is recognized for its virulence factors, including various proteins that play important roles in pathogenesis. Research on this bacterium is significant as it provides insights into host-pathogen interactions and potential targets for vaccine development. S. equi subsp. equi has evolved from S. equi subsp. zooepidemicus and shares significant genomic content with other streptococcal species, making it an important comparative model for evolutionary studies of bacterial pathogens .

How are recombinant S. equi proteins typically expressed and purified for research?

Recombinant S. equi proteins are commonly expressed using Escherichia coli expression systems, particularly E. coli BL21(DE3), which has proven to be a suitable expression host for S. equi proteins . The methodology typically involves:

• Cloning the gene of interest into an appropriate expression vector

• Transformation into competent E. coli cells

• Induction of protein expression (commonly with IPTG)

• Cell lysis to release the expressed protein

• Purification through affinity chromatography, typically using His-tag purification systems

• Protein characterization via SDS-PAGE and Western blotting

The E. coli expression system has demonstrated efficacy not only for protein production but also as a potential delivery vehicle for vaccination purposes, as studies have shown enhanced immunogenicity when using the whole recombinant E. coli cells expressing S. equi proteins compared to purified proteins alone .

What molecular detection methods are most effective for identifying S. equi subsp. equi and its virulence factors?

The most effective molecular detection methods for S. equi subsp. equi include:

• PCR-based detection using species-specific primers:

  • 16S rRNA gene amplification for genus confirmation

  • seM gene amplification (679 bp product) for S. equi subsp. equi

  • sodA gene amplification (235 bp product) for S. equi subsp. zooepidemicus

• Real-time PCR, which offers increased sensitivity and specificity compared to conventional culture methods

• Sequence analysis of virulence genes for strain typing and characterization

These molecular methods are significantly more rapid than traditional culture techniques, which can be challenging due to the fastidious nature of the organism. Columbia nalidixic agar has been shown to improve growth and facilitate isolation of the bacterium . For comprehensive identification, a combination of microbiological culture and molecular confirmation via PCR is recommended for definitive diagnosis and characterization of virulence factors .

What are the optimal experimental conditions for expressing recombinant S. equi proteins in E. coli systems?

Optimal experimental conditions for expressing recombinant S. equi proteins in E. coli systems include:

• Strain selection: E. coli BL21(DE3) has proven particularly effective for S. equi protein expression due to its reduced protease activity and compatibility with T7 promoter-based expression systems .

• Expression vector considerations:

  • pET vectors containing T7 promoters provide high-level expression

  • Inclusion of affinity tags (His-tag) facilitates downstream purification

  • Codon optimization may be necessary for efficient expression

• Culture conditions:

  • Growth temperature: 37°C for initial growth, reducing to 25-30°C during induction to minimize inclusion body formation

  • Media: Enriched media such as LB or 2xYT with appropriate antibiotics

  • Induction: IPTG concentration typically 0.1-1.0 mM, with induction at OD600 of 0.6-0.8

• Protein solubility enhancement:

  • Co-expression with chaperone proteins if the target protein tends to form inclusion bodies

  • Addition of mild detergents or osmolytes to the lysis buffer

For specific applications like vaccine development, both live and inactivated recombinant E. coli expressing S. equi proteins have shown efficacy, with studies indicating that both forms can enhance the humoral immune response compared to purified protein alone .

How should researchers design challenge experiments to evaluate vaccine potential of recombinant S. equi proteins?

Design of challenge experiments to evaluate vaccine potential should follow this methodological framework:

• Animal model selection:

  • Mice models are suitable for initial screening

  • Horse models are essential for subsequent validation

  • Consider age, breed, and naive status (no previous exposure to S. equi)

• Vaccination groups design:

  • Recombinant protein expressed in live delivery system (e.g., recombinant E. coli)

  • Inactivated recombinant bacteria with adjuvant (e.g., alumen)

  • Purified recombinant protein with adjuvant

  • Inactivated whole-cell pathogen (bacterin) with adjuvant

  • Negative control (unvaccinated)

• Immunization protocol:

  • Prime-boost schedule (typically 2-3 immunizations)

  • Consistent routes of administration (intramuscular, intranasal, etc.)

  • Standardized dose determination

• Challenge parameters:

  • Sufficient post-vaccination period (3-4 weeks) to develop immunity

  • Controlled challenge dose of virulent S. equi

  • Standardized route of challenge (typically intranasal for S. equi)

• Outcome measurements:

  • Antibody titers (IgG, IgA levels) via ELISA

  • Clinical sign monitoring and scoring system

  • Bacterial recovery from tissues

  • Survival/protection rates

  • Cytokine profiles for immune response characterization

Previous studies have demonstrated that mice vaccinated with recombinant E. coli expressing S. equi proteins developed protective responses against S. equi infection, with significantly higher IgG levels observed in groups receiving E. coli expressing recombinant proteins compared to purified proteins or bacterin vaccines . This approach can then be validated in the natural host (horses) following successful mouse trials.

What controls are essential when evaluating immune responses to recombinant S. equi proteins?

Essential controls for evaluating immune responses to recombinant S. equi proteins include:

• Negative controls:

  • Unvaccinated animals (naive control)

  • Vector-only control (E. coli expressing empty vector)

  • Adjuvant-only control to distinguish adjuvant effects from protein-specific responses

• Positive controls:

  • Commercially available vaccine (if available)

  • Inactivated whole-cell preparation (bacterin)

  • Convalescent serum from naturally infected/recovered animals

• Technical controls:

  • Isotype controls for antibody detection assays

  • Known positive and negative samples for assay validation

  • Background subtraction controls for ELISA assays

• Cross-reactivity controls:

  • Related but distinct proteins to assess specificity

  • Related bacterial species (e.g., S. equi subsp. zooepidemicus) to evaluate cross-protection

• Longitudinal controls:

  • Pre-immune sera from the same animals

  • Time-matched samples from control groups

Implementing these controls is critical for distinguishing protein-specific immune responses from non-specific effects. Research has shown that E. coli cells can enhance the immune response against S. equi, potentially through interaction with pathogen-associated molecular patterns (PAMPs) that activate innate immune receptors . Therefore, proper vector controls are particularly important when using bacterial expression systems as delivery vehicles.

How should researchers analyze antibody response data following immunization with recombinant S. equi proteins?

Analysis of antibody response data following immunization should follow these methodological steps:

• Quantitative analysis:

  • ELISA for specific IgG, IgA, and IgM measurements

  • Endpoint titration to determine antibody titers

  • Avidity assays to assess antibody maturation

  • Western blot for qualitative confirmation of specificity

• Statistical approaches:

  • Two-way ANOVA for comparing multiple groups over time

  • Appropriate post-hoc tests (Tukey's, Bonferroni) for multiple comparisons

  • Non-parametric tests (Mann-Whitney, Kruskal-Wallis) for non-normally distributed data

  • Correlation analysis between antibody levels and protection outcomes

• Reporting standards:

  • Present geometric mean titers with 95% confidence intervals

  • Include seroconversion rates (fold-increase over baseline)

  • Report both raw values and log-transformed data when appropriate

• Advanced analysis:

  • Distinguish between different IgG subclasses (IgG1, IgG2a/b) to characterize Th1/Th2 bias

  • Perform epitope mapping to identify immunodominant regions

  • Conduct neutralization assays to assess functional antibody activity

When analyzing antibody responses, it's critical to note that significantly higher IgG levels have been observed in animals vaccinated with recombinant E. coli expressing S. equi proteins compared to those receiving purified proteins or bacterin vaccines . This suggests that the bacterial delivery system may provide adjuvant effects through PAMPs that enhance immunogenicity, a factor that should be considered when interpreting comparative data.

What approaches should be used to distinguish protective versus non-protective immune responses?

Distinguishing protective versus non-protective immune responses requires a multi-faceted approach:

• Correlates of protection analysis:

  • Determination of threshold antibody titers associated with protection

  • ROC curve analysis to establish cutoff values

  • Calculation of positive and negative predictive values

• Functional assays:

  • Opsonophagocytic killing assays to measure antibody function

  • Complement-dependent bactericidal assays

  • Neutralization of specific virulence factors

  • T-cell proliferation assays to assess cellular immunity

• Challenge study endpoints:

  • Clinical protection scoring systems

  • Bacterial burden quantification in target tissues

  • Survival/recovery rates correlation with immune parameters

  • Time-to-clearance measurements

• Multivariate analysis:

  • Principal component analysis to identify patterns in immune responses

  • Machine learning approaches to identify combinatorial protective signatures

  • Cox proportional hazards models for time-to-event outcomes

• Passive transfer studies:

  • Transfer of serum from immunized to naive animals to assess antibody-mediated protection

  • Adoptive transfer of T cells to evaluate cellular immunity contribution

Research with S. equi has shown that while all vaccination approaches may elicit antibody responses, the quality and functional capacity of these antibodies can vary significantly. For example, studies have demonstrated that mice receiving E. coli expressing recombinant S. equi proteins developed protective responses against S. equi infection, suggesting that both quantity and functional quality of antibodies contribute to protection .

How can researchers effectively compare immunogenicity data across different recombinant protein expression systems?

Effective comparison of immunogenicity data across different expression systems requires:

• Standardization protocols:

  • Protein quantification using consistent methods (BCA, Bradford)

  • Endotoxin level determination and normalization

  • Confirmation of protein integrity and conformation

  • Consistent adjuvant selection when applicable

• Comparative analysis framework:

  • Dose normalization (μg of antigen per dose)

  • Time-matched sampling points

  • Parallel assay execution for all samples

  • Side-by-side testing in identical animal models

• System-specific considerations:

  • For E. coli systems: Account for LPS and other PAMPs as potential adjuvants

  • For eukaryotic systems: Consider post-translational modifications

  • For in vivo delivery systems: Account for persistence and replication

• Statistical approaches:

  • ANCOVA with system type as a factor and dose as covariate

  • Mixed-effects models for longitudinal comparisons

  • Meta-analysis techniques for combining data across studies

• Reporting standards:

  Expression System	Advantages	Limitations	Normalization Factors
  E. coli	High yield, simple	Lacks PTMs, endotoxin	LPS content
  Yeast	PTMs, secretion	Hyperglycosylation	Glycosylation patterns
  Mammalian	Native-like PTMs	Low yield, cost	Cell line, glycosylation
  Cell-free	Rapid, controllable	Scale limitations	Batch consistency

Research has demonstrated that the expression system can significantly impact immunogenicity, with studies showing that E. coli expressing recombinant S. equi proteins induced higher IgG responses than purified recombinant protein formulations . This suggests that the bacterial delivery system provides additional immunostimulatory signals that should be accounted for when comparing across expression platforms.

How does the GTPase Era protein of S. equi contribute to bacterial physiology and pathogenesis?

GTPase Era (essential for retention of antibiotic A) proteins are highly conserved bacterial GTPases that function as molecular switches in various cellular processes. In S. equi, the Era protein likely contributes to:

• Ribosomal assembly and maturation:

  • Binding to 16S rRNA and the 30S ribosomal subunit

  • Regulation of translation initiation

  • Quality control of ribosome biogenesis

• Cell cycle regulation:

  • Coordination of cell division with ribosome assembly

  • Checkpoint control for DNA replication and segregation

  • Regulation of chromosome partitioning

• Stress response and adaptation:

  • Metabolic adaptation during nutrient limitation

  • Response to environmental changes

  • Potential role in antibiotic resistance mechanisms

• Virulence modulation:

  • Regulation of virulence gene expression

  • Contribution to stress survival during host infection

  • Potential interaction with host innate immune factors

Research methodology to investigate these functions typically involves:

• Generation of conditional mutants (as complete knockout may be lethal)

• Site-directed mutagenesis of key functional residues

• Protein-protein interaction studies

• Ribosome profiling and translational efficiency analysis

• Structural studies using X-ray crystallography or cryo-EM

While the search results don't provide specific information about the Era protein in S. equi, studies in related streptococcal species suggest that GTPases like Era are essential for bacterial viability and represent potential targets for antimicrobial development.

What are the challenges in developing stable expression systems for potentially toxic bacterial proteins?

Developing stable expression systems for potentially toxic bacterial proteins presents several challenges requiring specialized approaches:

• Toxicity management strategies:

  • Tight regulation using stringent promoters (e.g., arabinose-inducible pBAD)

  • Use of low-copy plasmids to minimize basal expression

  • Fusion with solubility tags that may reduce toxicity (MBP, SUMO, thioredoxin)

  • Co-expression with binding partners or inhibitors

• Expression strain considerations:

  • Strains with reduced proteolysis (BL21, Rosetta)

  • Strains with specific mutations that confer tolerance to toxic proteins

  • C41(DE3) and C43(DE3) strains specifically designed for toxic protein expression

• Induction optimization:

  • Reduced temperature (16-25°C) during induction

  • Lower inducer concentrations

  • Shorter induction periods

  • Late log-phase induction to minimize impact on cell growth

• Alternative expression technologies:

  • Cell-free protein synthesis systems

  • In vitro transcription-translation coupled systems

  • Periplasmic targeting to reduce cytoplasmic toxicity

  • Secretion-based systems in eukaryotic hosts

• Experimental validation:

  • Growth curve analysis during expression

  • Plasmid stability testing over multiple generations

  • Assessment of protein accumulation vs. cell viability

  • Viability staining of expressing cultures

These approaches have been successfully employed for various streptococcal virulence factors. For instance, research with S. equi has demonstrated successful expression of potentially harmful proteins like the M protein (SeM) in E. coli BL21(DE3), indicating that with proper optimization, even challenging proteins can be expressed in recombinant systems .

What are the critical considerations for designing multi-antigen recombinant vaccines against S. equi?

Designing multi-antigen recombinant vaccines against S. equi requires careful consideration of several critical factors:

• Antigen selection criteria:

  • Conservation across strains and serotypes

  • Expression during different stages of infection

  • Functional role in virulence or colonization

  • Demonstrated immunogenicity in natural infection

  • Minimal cross-reactivity with commensal flora

• Expression strategy optimization:

  • Polycistronic constructs vs. individual protein expression

  • Protein fusion approaches (chemical conjugation or genetic fusion)

  • Relative expression levels of different antigens

  • Subcellular localization (surface display vs. secretion)

• Immunological balance considerations:

  • Th1/Th2/Th17 response balancing

  • Avoiding immunodominance of certain epitopes

  • Preventing epitope competition or suppression

  • Ensuring broad epitope coverage for diverse MHC haplotypes

• Formulation and delivery strategies:

  • Adjuvant selection for optimal immune stimulation

  • Bacterial vector systems (live attenuated or killed)

  • Prime-boost approaches with heterologous platforms

  • Mucosal vs. systemic delivery route optimization

• Safety and efficacy assessment:

  • Monitoring for enhanced disease or immunopathology

  • Testing in immunocompromised models

  • Long-term immunity evaluation

  • Cross-protection against heterologous strains

Research has demonstrated that combining multiple antigens can enhance protection against S. equi infection. Studies have identified several promising vaccine candidates including SeM protein, fibronectin-binding proteins (FNZ and SFS), which when combined may provide superior protection compared to single-antigen approaches . The ideal multi-antigen vaccine would target multiple virulence mechanisms simultaneously while generating both mucosal and systemic immunity.

What are the advantages and limitations of using recombinant E. coli as a delivery system for S. equi antigens?

Using recombinant E. coli as a delivery system for S. equi antigens presents distinct advantages and limitations:

Advantages:

• Enhanced immunogenicity: Studies have demonstrated that recombinant E. coli expressing S. equi proteins induce significantly higher IgG levels than purified proteins or bacterin vaccines .

• Adjuvant effect: E. coli cells provide natural adjuvant properties through PAMPs that interact with pattern recognition receptors, triggering innate immune responses and enhancing adaptive immunity .

• Cost-effectiveness: Production of recombinant E. coli is less expensive than purified protein production, offering a potential low-cost vaccine platform .

• Versatility: Can be used live or inactivated, with both forms showing enhanced humoral responses compared to purified proteins .

• Mucosal immunity: Bacterial vectors can stimulate mucosal immune responses when administered through appropriate routes.

Limitations:

• Safety concerns: Live bacterial vectors pose potential risks of reversion to virulence or environmental release.

• Regulatory hurdles: Genetically modified organisms face stringent regulatory requirements for approval.

• Pre-existing immunity: Prior exposure to E. coli may affect vaccine efficacy through vector neutralization.

• Strain-dependent variation: Expression levels and immunogenicity can vary between different E. coli strains.

• Endotoxin content: LPS in E. coli preparations may cause adverse reactions, requiring careful purification or detoxification.

Research has shown that both live and inactivated recombinant E. coli expressing S. equi proteins can enhance the humoral immune response compared to purified protein antigens or traditional bacterin vaccines, highlighting the potential of this approach for strangles vaccine development .

How does antibody response to recombinant S. equi proteins correlate with protection against infection?

The correlation between antibody responses to recombinant S. equi proteins and protection involves complex mechanisms:

• Quantitative correlations:

  • Higher serum IgG levels generally correlate with increased protection

  • Studies have shown that animals receiving recombinant E. coli expressing S. equi proteins develop significantly higher IgG levels and demonstrate better protection against challenge

  • Threshold antibody levels may be required for effective protection

• Qualitative factors affecting protection:

  • Antibody avidity (functional affinity) increases over time and correlates with protection

  • IgG subclass distribution affects effector functions (opsonization, complement activation)

  • Epitope specificity determines neutralizing capacity

  • Mucosal IgA may be critical for preventing initial colonization

• Mechanistic correlates:

  • Opsonophagocytic activity correlates with clearance of S. equi

  • Neutralization of specific virulence factors (e.g., M-protein) prevents colonization

  • Antibodies against adhesins can block initial attachment

  • Complement-activating antibodies enhance bacterial killing

• Limitations of antibody-based protection:

  • Some protected animals may show low antibody levels, suggesting cellular immunity involvement

  • Antibody escape through antigenic variation

  • Importance of timing: pre-existing antibodies versus developing response

The relationship between antibody response and protection is not always linear. Research with recombinant S. equi proteins has shown that while all vaccinated mice developed protective responses against S. equi infection, those receiving E. coli expressing recombinant proteins demonstrated significantly higher IgG levels and better protection, suggesting that both quantity and functional quality of antibodies contribute to effective immunity .

What methodologies are most effective for assessing cross-protection between S. equi subspecies following recombinant protein immunization?

Effective methodologies for assessing cross-protection between S. equi subspecies include:

• In vitro cross-reactivity assessment:

  • ELISA using antigens from multiple subspecies (equi, zooepidemicus)

  • Western blot analysis to identify cross-reactive proteins

  • Epitope mapping to identify conserved versus subspecies-specific regions

  • Competitive binding assays to determine shared epitopes

• Functional antibody assessment:

  • Cross-opsonophagocytic killing assays against multiple subspecies

  • Growth inhibition assays with sera from immunized animals

  • Bacterial adhesion inhibition tests to evaluate cross-protective potential

  • Neutralization of shared virulence factors

• Cross-challenge study design:

  • Heterologous challenge with different subspecies following immunization

  • Sequential challenge with multiple subspecies

  • Mixed challenge with combined subspecies

  • Dose-response studies to determine protection threshold

• Comparative genomic and proteomic approaches:

  • Identification of conserved antigens through genomic comparison

  • Proteomic analysis of surface-exposed proteins

  • Immunoproteomics to identify cross-reactive antigens

  • Structural biology to determine epitope conservation

• Advanced analytical methods:

  • Antibody repertoire analysis using next-generation sequencing

  • Systems serology to characterize antibody functionality profiles

  • Machine learning approaches to identify protective signatures

S. equi subsp. equi and S. equi subsp. zooepidemicus share significant genomic content, making cross-protection assessment particularly relevant . Molecular characterization using PCR for specific genes (seM for S. equi subsp. equi and sodA for S. equi subsp. zooepidemicus) can help distinguish between the subspecies in challenge studies . Additionally, potential cross-protection may exist due to conserved proteins between these closely related pathogens, which could be beneficial for developing broader protective vaccines.

What novel approaches might improve the stability and immunogenicity of recombinant S. equi proteins?

Novel approaches to improve stability and immunogenicity of recombinant S. equi proteins include:

• Protein engineering strategies:

  • Computational design of stabilizing mutations

  • Disulfide bond engineering to enhance thermostability

  • Surface charge optimization to reduce aggregation

  • Glycosylation site addition for increased solubility

  • Epitope-focused design to enhance protective responses

• Advanced expression systems:

  • Cell-free protein synthesis for difficult-to-express proteins

  • Non-conventional yeast platforms (Pichia pastoris, Kluyveromyces lactis)

  • Baculovirus expression systems for complex proteins

  • Plant-based expression systems for cost-effective production and oral delivery

• Innovative formulation approaches:

  • Nanoparticle encapsulation for controlled release

  • Self-assembling protein nanoparticles for multivalent display

  • Liposomal formulations for enhanced uptake

  • Biomimetic particle systems (virus-like particles, bacterial ghosts)

• Adjuvant technology:

  • TLR agonist combinations tailored to streptococcal immunity

  • Mucosal adjuvants for intranasal delivery

  • Cytokine-adjuvant fusions for targeted immune modulation

  • Microbiome-based adjuvants that enhance colonization resistance

• Delivery innovations:

  • Needle-free delivery systems (jet injectors, microneedle patches)

  • Mucosal delivery vehicles (chitosan nanoparticles, bacterial ghosts)

  • Prime-pull vaccination strategies for mucosal immunity

  • In situ vaccination approaches

Research has demonstrated that utilizing E. coli as both expression and delivery systems for S. equi proteins enhances immunogenicity compared to purified proteins alone . Future approaches could build on this by combining the beneficial PAMP-mediated stimulation with advanced formulation technologies to further enhance stability and immunogenicity while maintaining the cost advantages.

How might next-generation sequencing and comparative genomics inform the selection of novel S. equi vaccine candidates?

Next-generation sequencing and comparative genomics can inform S. equi vaccine candidate selection through:

• Pan-genome analysis:

  • Identification of core versus accessory genome components

  • Detection of conserved antigens across diverse clinical isolates

  • Analysis of strain-specific antigens for coverage assessment

  • Tracking of antigen conservation over time and geographic distribution

• Virulence gene identification:

  • Comparative analysis with related species to identify virulence factors

  • Identification of genes upregulated during infection

  • Detection of horizontally acquired virulence islands

  • Analysis of selection pressure on potential antigen-encoding genes

• Reverse vaccinology approaches:

  • In silico prediction of surface-exposed or secreted proteins

  • Epitope prediction and population coverage analysis

  • Structural biology integration for epitope accessibility assessment

  • Exclusion of human homologs to avoid autoimmunity

• Transcriptomic applications:

  • RNA-Seq to identify genes expressed during different infection stages

  • Identification of genes upregulated under host-mimicking conditions

  • Differential expression analysis between virulent and avirulent strains

  • Discovery of non-coding RNAs involved in virulence regulation

• Functional genomics integration:

  • TraDIS/Tn-Seq to identify essential genes during infection

  • CRISPR-based screens for virulence factor identification

  • Proteomic validation of in silico predictions

  • Immunoproteomic identification of antigens recognized by convalescent sera

Studies on S. equi have already utilized molecular approaches for characterization of virulence genes using PCR for specific targets like seM and sodA genes . As S. equi subsp. equi shares approximately 80% of its genome with S. pyogenes , comparative genomic approaches could leverage knowledge from this well-studied human pathogen to identify novel vaccine candidates for S. equi.

What are the prospects for developing universal vaccines against multiple streptococcal species using conserved antigens?

The prospects for developing universal streptococcal vaccines using conserved antigens involve:

• Cross-species antigen identification:

  • Genomic analysis of core streptococcal proteins

  • Identification of structurally conserved epitopes across species

  • Focus on essential proteins with limited antigenic variation

  • Targeting of metabolic enzymes or ABC transporters with high conservation

• Technological approaches:

  • Structure-based vaccine design for conserved epitopes

  • Consensus sequence approaches for variable antigens

  • Chimeric proteins incorporating epitopes from multiple species

  • Computationally optimized broadly protective antigen design

• Delivery and formulation strategies:

  • Multi-strain bacterial vectors expressing conserved antigens

  • mRNA vaccines encoding conserved streptococcal proteins

  • Prime-boost approaches with species-specific followed by conserved antigens

  • Adjuvant selection for broad-spectrum immunity

• Evaluation framework:

  • Sequential challenge with multiple streptococcal species

  • Assessment of protection across evolutionary distance

  • Standardized immune correlate assays across species

  • Field testing in regions with multiple endemic streptococcal diseases

• Key challenges and solutions:

  Challenge	Potential Solution
  Antigenic variation	Focus on conserved functional domains
  Host-specific pathogenesis	Target conserved colonization mechanisms
  Different infection sites	Design for both mucosal and systemic immunity
  Varying immune evasion strategies	Target multiple pathways simultaneously
  Cross-reactivity with commensal streptococci	Careful epitope selection and validation